Gilead Sciences — Ethics Grade C-

Gilead Sciences receives an overall ethics grade of C- (42/100) on CancelCo's corporate accountability database. Sector: Healthcare. Market cap: Large Cap.

Category scores

• labor: 60
• privacy: 80
• consumer: 20
• environment: 75
• humanRights: 45

Documented incidents (3)

• HIV Drug Monopoly Allegations (high, 2023) — Lawsuits alleged that Gilead struck deals with competitors to delay the entry of generic versions of its HIV medications, keeping prices exorbitant for patients.
• Truvada Patent Delay Claims (high, 2019) — Evidence suggested Gilead delayed a safer version of its HIV drug, Truvada, to maximize profits on the older version before the patent expired.
• Price Gouging of Sovaldi (medium, 2015) — Pricing its Hepatitis C drug at $1,000 per pill ($84,000 per course) led to a US Senate investigation concluding the company prioritized profit over patient access.

Documented good deeds

• Low-Income HIV Access — Donating 2.4 million bottles of Truvada annually to the CDC for uninsured Americans.

Ethical alternatives

• ViiV Healthcare — Higher commitment to tiered pricing in low-income countries.